MedPath

FUJITA HEALTH UNIVERSITY

FUJITA HEALTH UNIVERSITY logo
🇯🇵Japan
Ownership
Private
Established
1968-01-01
Employees
501
Market Cap
-
Website
http://www.fujita-hu.ac.jp

Clinical Trials

148

Active:0
Completed:63

Trial Phases

5 Phases

Phase 1:2
Phase 2:5
Phase 3:1
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (145 trials with phase data)• Click on a phase to view related trials

Not Applicable
133 (91.7%)
Phase 2
5 (3.4%)
Phase 4
4 (2.8%)
Phase 1
2 (1.4%)
Phase 3
1 (0.7%)

A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease

Not Applicable
Recruiting
Conditions
Parkinson's Disease (PD)
Interventions
First Posted Date
2025-09-12
Last Posted Date
2025-09-12
Lead Sponsor
Fujita Health University
Target Recruit Count
24
Registration Number
NCT07170475
Locations
🇯🇵

Fujita Health University, Toyoake, Aichi-ken, Japan

Thrombus Aspiration and Pathology and OCT Study

Recruiting
Conditions
Acute Coronary Syndrome
First Posted Date
2025-09-03
Last Posted Date
2025-09-03
Lead Sponsor
Fujita Health University
Target Recruit Count
200
Registration Number
NCT07151976
Locations
🇯🇵

Fujita Health University, Toyoake, Aichi-ken, Japan

CT-Angiography Plaque Characteristics and Events in Deferral Patients by Invasive Fractional Flow Reserve

Recruiting
Conditions
Patient Preference
First Posted Date
2024-07-18
Last Posted Date
2025-01-03
Lead Sponsor
Fujita Health University
Target Recruit Count
400
Registration Number
NCT06508697
Locations
🇯🇵

Fujita Health University, Toyoake, Aichi, Japan

Safety and Immunogenicity of EXG-5003

Phase 1
Completed
Conditions
COVID-19
First Posted Date
2021-04-28
Last Posted Date
2023-01-26
Lead Sponsor
Fujita Health University
Target Recruit Count
40
Registration Number
NCT04863131
Locations
🇯🇵

Fujita Health University Hospital, Toyoake, Aichi, Japan

Comparison Between OFDI and IVUS in PCI Guidance for Biolimus A9 Eluting Stent Implantation

Phase 2
Conditions
Coronary Artery Disease
First Posted Date
2017-09-25
Last Posted Date
2017-09-25
Lead Sponsor
Fujita Health University
Target Recruit Count
96
Registration Number
NCT03292081
Locations
🇯🇵

Fujita Health University, Toyoake, Japan

  • Prev
  • 1
  • 2
  • Next

News

Adipose-Derived Stem Cell Injections Show Promise in Treating Inflammatory Eye Diseases

Japanese researchers demonstrate that local injections of adipose-derived mesenchymal stem cells effectively reduce inflammation in ocular graft-versus-host disease, offering a safer alternative to corticosteroids.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.